HHS has proposed increasing from 100 to 200 the patient limit for qualified practitioners who prescribe buprenorphine-based medication-assisted treatment under the Controlled Substances Act to expand access to treatment for opioid use disorders.  Buprenorphine is an opioid medication used to treat opioid addiction that can be dispensed for take-home use, by prescription. The proposed rule outlines eligibility requirements for the higher patient limit, including standards related to certification, practice setting, and adherence to evidence-based treatment guidelines, among others. Comments will be accepted until May 31, 2016.